(Total Views: 470)
Posted On: 08/21/2020 8:09:00 AM
Post# of 653
$RLFTF The Results
Trial 3 includes a series of 21 consecutive patients with Acute Respiratory Failure in Critical COVID-19 and multiple co-morbidities, treated with intravenous VIP.
So far, 19 out of 21 of them have survived. At the moment, August 20, 7 patients were discharged from the hospital, 7 sent to intermediate care, and 5 remain in the ICU. As often in those cases, blood oxygenation is very low and can be lethal.
As you can see below, the use of RLF-100™, dramatically improved blood oxygenation.
A promising anti-COVID drug you have probably never heard of
https://medium.com/@alexschroeti/a-promising-...cae8072da6
Trial 3 includes a series of 21 consecutive patients with Acute Respiratory Failure in Critical COVID-19 and multiple co-morbidities, treated with intravenous VIP.
So far, 19 out of 21 of them have survived. At the moment, August 20, 7 patients were discharged from the hospital, 7 sent to intermediate care, and 5 remain in the ICU. As often in those cases, blood oxygenation is very low and can be lethal.
As you can see below, the use of RLF-100™, dramatically improved blood oxygenation.
A promising anti-COVID drug you have probably never heard of
https://medium.com/@alexschroeti/a-promising-...cae8072da6
(0)
(0)
$MJ
